[go: up one dir, main page]

DE602005016810D1 - Impfstoff zur prävention und behandlung von einer hiv-infektion - Google Patents

Impfstoff zur prävention und behandlung von einer hiv-infektion

Info

Publication number
DE602005016810D1
DE602005016810D1 DE602005016810T DE602005016810T DE602005016810D1 DE 602005016810 D1 DE602005016810 D1 DE 602005016810D1 DE 602005016810 T DE602005016810 T DE 602005016810T DE 602005016810 T DE602005016810 T DE 602005016810T DE 602005016810 D1 DE602005016810 D1 DE 602005016810D1
Authority
DE
Germany
Prior art keywords
vaccine
prevention
treatment
hiv infection
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005016810T
Other languages
German (de)
English (en)
Inventor
Helge Abrecht
Martine Delchambre
Martine Marchand
Nathalie Louise Mathy
Philippe Jean Gervais Permanne
Gerald Hermann Voss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of DE602005016810D1 publication Critical patent/DE602005016810D1/de
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602005016810T 2004-08-05 2005-08-03 Impfstoff zur prävention und behandlung von einer hiv-infektion Active DE602005016810D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine
PCT/EP2005/008434 WO2006013106A2 (en) 2004-08-05 2005-08-03 Vaccine for prevention and treatment of hiv-infection

Publications (1)

Publication Number Publication Date
DE602005016810D1 true DE602005016810D1 (de) 2009-11-05

Family

ID=32982606

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005016810T Active DE602005016810D1 (de) 2004-08-05 2005-08-03 Impfstoff zur prävention und behandlung von einer hiv-infektion

Country Status (31)

Country Link
US (2) US7612173B2 (xx)
EP (3) EP2280073B1 (xx)
JP (3) JP2008507987A (xx)
KR (1) KR101501495B1 (xx)
CN (2) CN102633866B (xx)
AR (2) AR050102A1 (xx)
AT (1) ATE443769T1 (xx)
AU (1) AU2005268856B2 (xx)
BR (1) BRPI0514108A (xx)
CA (1) CA2575898C (xx)
CY (1) CY1109667T1 (xx)
DE (1) DE602005016810D1 (xx)
DK (1) DK1773999T3 (xx)
ES (3) ES2445453T3 (xx)
GB (1) GB0417494D0 (xx)
HR (1) HRP20090678T1 (xx)
IL (2) IL180947A0 (xx)
MA (1) MA28983B1 (xx)
MX (1) MX2007001515A (xx)
MY (1) MY145614A (xx)
NO (1) NO20070988L (xx)
NZ (1) NZ552976A (xx)
PE (1) PE20060577A1 (xx)
PL (1) PL1773999T3 (xx)
PT (1) PT1773999E (xx)
RU (1) RU2441878C2 (xx)
SG (1) SG155206A1 (xx)
SI (1) SI1773999T1 (xx)
TW (1) TWI365191B (xx)
WO (1) WO2006013106A2 (xx)
ZA (1) ZA200700771B (xx)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
EP1039880A1 (en) * 1998-10-23 2000-10-04 Idea Innovative Dermale Applikationen GmbH Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP2008519784A (ja) * 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
AR053275A1 (es) * 2005-05-12 2007-04-25 Glaxo Group Ltd Composicion de vacuna
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
WO2007133573A1 (en) * 2006-05-09 2007-11-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hiv-1 immunogenic compositions
DK2520168T3 (da) 2006-07-21 2014-04-14 California Inst Of Techn Målrettet gen-tilførsel til dendrit-cellevaccination
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CL2008000611A1 (es) * 2007-03-02 2008-09-05 Glaxosmithkline Biolog Sa Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
WO2008109785A2 (en) * 2007-03-06 2008-09-12 Rutgers, The State University Hiv reverse transcriptase compositions and methods
WO2008118936A2 (en) * 2007-03-26 2008-10-02 International Aids Vaccine Initiative Method of elicting immune response with a modified mva viral hiv-1 vector
CN101678091A (zh) 2007-05-24 2010-03-24 葛兰素史密丝克莱恩生物有限公司 冷冻干燥的抗原组合物
EP2247307A1 (en) * 2007-12-21 2010-11-10 GlaxoSmithKline Biologicals S.A. Vaccine
AU2009270771B2 (en) * 2008-07-16 2012-08-23 Baylor Research Institute HIV vaccine based on targeting maximized Gag and Nef to dendritic cells
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010029562A1 (en) 2008-09-09 2010-03-18 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
AU2010276194B2 (en) 2009-07-24 2012-02-02 Immune Design Corp Lentiviral vectors pseudotyped with a Sindbis virus envelope glycoprotein
SG184188A1 (en) 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine
KR20180082633A (ko) * 2010-05-14 2018-07-18 박스알타 인코퍼레이티드 Ｏｓｐａ 키메라 및 백신에서 그의 용도
EP2621528A1 (en) 2010-09-27 2013-08-07 GlaxoSmithKline Biologicals S.A. Vaccine
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
AU2013237900B2 (en) 2012-03-30 2017-07-27 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
EP2978449B1 (en) * 2013-03-26 2021-09-08 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
ES2930667T3 (es) 2014-07-11 2022-12-21 Gilead Sciences Inc Moduladores de receptores de tipo Toll para el tratamiento de VIH
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
US11666651B2 (en) 2019-11-14 2023-06-06 Aelix Therapeutics, S.L. Prime/boost immunization regimen against HIV-1 utilizing a multiepitope T cell immunogen comprising Gag, Pol, Vif, and Nef epitopes
EP4126028A1 (en) 2020-03-27 2023-02-08 Svenska Vaccinfabriken Produktion AB Compositions and methods for treating and preventing coronaviruses
PE20241071A1 (es) 2021-01-14 2024-05-13 Gilead Sciences Inc Vacunas contra el vih y metodos de uso
US20230295244A1 (en) 2021-09-29 2023-09-21 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronaviruses

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
JP4028593B2 (ja) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
DE69434151D1 (de) 1993-05-18 2004-12-30 Biomolecular Res Inst Ltd Therapeutische inhaltsstoffe
RO115731B1 (ro) 1993-11-17 2000-05-30 Deutsche Om Arzneimittel Gmbh Derivati de dizaharide glucozamina beta (1 - 6), procedeu pentru prepararea acestora si compozitie farmaceutica
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1996002555A1 (en) 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2654522C (en) 1997-08-29 2014-01-28 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as exipient
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
EP1104310B1 (en) 1998-08-04 2009-07-01 The Henry M. Jackson Foundation for the advancement of Military Medicine, Inc. Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
CA2393861A1 (en) 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
DK1240186T3 (da) 1999-12-23 2010-05-31 Medical Res Council Forbedringer i eller relateret til immunrespons mod HIV
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
EP1320621A4 (en) 2000-09-15 2005-11-23 Merck & Co Inc ADVANCED FIRST-GENE ADENOVIRAL VACCINES EXPRESSING CODON OPTIMIZATION OF THE GAG, POL AND NEF PROTEINS OF HIV-1 AND CHANGES THEREOF
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
WO2003025003A2 (en) * 2001-09-20 2003-03-27 Glaxo Group Limited Hiv-gag codon-optimised dna vaccines
CA2466431C (en) 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
WO2003046142A2 (en) 2001-11-26 2003-06-05 Avigen, Inc. Methods for producing stocks of recombinant aav virions
US20030190308A1 (en) 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
WO2003080112A2 (en) * 2002-03-19 2003-10-02 Powdermed Limited Imidazoquinolineamines as adjuvants in hiv dna vaccination
EP1511768B1 (en) * 2002-06-11 2007-04-11 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB0225786D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
AU2004276559A1 (en) 2003-09-24 2005-04-07 Oxxon Therapeutics Limited HIV pharmaccines
US20050175627A1 (en) 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines

Also Published As

Publication number Publication date
ZA200700771B (en) 2009-04-29
WO2006013106A2 (en) 2006-02-09
MY145614A (en) 2012-03-15
CN101035897B (zh) 2012-02-01
MA28983B1 (fr) 2007-11-01
PL1773999T3 (pl) 2010-02-26
CA2575898C (en) 2015-09-29
EP2280073B1 (en) 2014-06-11
JP5629647B2 (ja) 2014-11-26
BRPI0514108A (pt) 2008-05-27
NZ552976A (en) 2010-01-29
EP2130921A3 (en) 2010-03-03
CN101035897A (zh) 2007-09-12
CA2575898A1 (en) 2006-02-09
TW200621806A (en) 2006-07-01
KR101501495B1 (ko) 2015-03-11
PE20060577A1 (es) 2006-08-07
AR080216A2 (es) 2012-03-21
US7612173B2 (en) 2009-11-03
HRP20090678T1 (hr) 2010-01-31
RU2441878C2 (ru) 2012-02-10
SG155206A1 (en) 2009-09-30
AU2005268856B2 (en) 2012-05-24
KR20070041765A (ko) 2007-04-19
ES2445453T3 (es) 2014-03-03
SI1773999T1 (sl) 2010-01-29
RU2007104088A (ru) 2008-09-10
ATE443769T1 (de) 2009-10-15
IL180947A0 (en) 2007-07-04
IL207575A0 (en) 2011-07-31
CY1109667T1 (el) 2014-08-13
CN102633866A (zh) 2012-08-15
EP2130921A2 (en) 2009-12-09
US20070243203A1 (en) 2007-10-18
AR050102A1 (es) 2006-09-27
GB0417494D0 (en) 2004-09-08
ES2486669T3 (es) 2014-08-19
CN102633866B (zh) 2015-04-15
TWI365191B (en) 2012-06-01
HK1108168A1 (en) 2008-05-02
NO20070988L (no) 2007-05-04
US20100184836A1 (en) 2010-07-22
WO2006013106A3 (en) 2006-08-17
EP1773999B1 (en) 2009-09-23
EP2130921B1 (en) 2013-11-20
PT1773999E (pt) 2009-12-16
JP2008507987A (ja) 2008-03-21
JP6007212B2 (ja) 2016-10-12
AU2005268856A1 (en) 2006-02-09
DK1773999T3 (da) 2010-01-18
MX2007001515A (es) 2007-09-07
ES2334044T3 (es) 2010-03-04
EP2280073A2 (en) 2011-02-02
EP1773999A2 (en) 2007-04-18
EP2280073A3 (en) 2011-06-29
JP2014239687A (ja) 2014-12-25
JP2011234722A (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
ATE443769T1 (de) Impfstoff zur prävention und behandlung von einer hiv-infektion
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE60234760D1 (de) Phenylindole zur behandlung von hiv
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
EP3908270A4 (en) COMBINATION OF DEXTROMETHORPHANE AND BUPROPION FOR THE TREATMENT OF DEPRESSION
EP1759710A4 (en) PREVENTIVE MEDICINE OR REMEDY FOR ARTHRITIS
EP1534074A4 (en) POLYTHERAPY FOR THE TREATMENT OF OBESITY
EP1742675A4 (en) TREATMENT OF BIOMEDICAL WASTE
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
DE602004010708D1 (de) Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
IL190478A0 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
PL1732604T3 (pl) Sposoby leczenia infekcji HIV
EP2135858A4 (en) COMPOSITION FOR TREATING INFECTIOUS DISEASES
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60139783D1 (de) Gen und pflanzenextrakte, wirksam zur behandlung und prävention von chlamydieninfektionen
EP2217573A4 (en) TREATMENT AND PREVENTION OF VIRAL INFECTIONS
EP1694364A4 (en) BREAST CANCER TREATMENT AND PREVENTION SYSTEM
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
EP1817039A4 (en) Treatment and prevention of epilepsy
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE443060T1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: MATHY, NATHALIE LOUISE, 1330 RIXENSART, BE

Inventor name: DELCHAMBRE, MARTINE, 1330 RIXENSART, BE

Inventor name: PERMANNE, PHILIPPE JEAN GERVAIS GHISLAIN, 1330, BE

Inventor name: MARCHAND, MARTINE, 1330 RIXENSART, BE

Inventor name: ABRECHT, HELGE, 1330 RIXENSART, BE

Inventor name: VOSS, GERALD HERMANN, 1330 RIXENSART, BE

8364 No opposition during term of opposition